Matching Categories

Search results found in:
 
 
US: 800.298.5699
Int'l: +1.240.747.3093
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 
Region: All Regions > Global
Category: All Categories > Life Sciences
(9140 reports matching your criteria)
4  5  6  7    9    11  12  13  
Juvenile Rheumatoid Arthritis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Juvenile Rheumatoid Arthritis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Liver Cirrhosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Liver Cirrhosis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Liver Transplantation-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Liver Transplantation. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Lymphoblastic Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Lymphoblastic Lymphoma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Malignant Glioma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Malignant Glioma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Mantle Cell Lymphoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Mantle Cell Lymphoma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Septic Shock-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Septic Shock. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Medullary Thyroid Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Medullary Thyroid Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Megaloblastic Anemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Megaloblastic Anemia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Metabolic Acidosis-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Metabolic Acidosis. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Metastatic Breast Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Metastatic Breast Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Metastatic Melanoma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Metastatic Melanoma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Recurrent Glioblastoma Multiforme (GBM)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... pipeline drugs and marketed drugs across the Recurrent Glioblastoma Multiforme (GBM). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different ...  |  read more...
USD 2,000
Refractory Multiple Myeloma-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Refractory Multiple Myeloma. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Pneumocystis Carinii Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Pneumocystis Carinii Pneumonia. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Pulmonary Edema-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Pulmonary Edema. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Metastatic Nonseminomatous Testicular Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... pipeline drugs and marketed drugs across the Metastatic Nonseminomatous Testicular Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different ...  |  read more...
USD 2,000
Metastatic Ovarian Cancer-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Metastatic Ovarian Cancer. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Myelodysplastic Syndrome-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Myelodysplastic Syndrome. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Myoclonic Seizures-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Myoclonic Seizures. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Nosocomial Infections-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Nosocomial Infections. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Ocular Hypertension-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Ocular Hypertension. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Ocular Inflammation-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... drugs across the Ocular Inflammation. A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions for the drugs ...  |  read more...
USD 2,000
Onychomycosis (Tinea Unguium)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... and marketed drugs across the Onychomycosis (Tinea Unguium). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different countries and regions ...  |  read more...
USD 2,000
Relapsing Multiple Sclerosis (RMS)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015
2/6/2015 | published by: DelveInsight
... pipeline drugs and marketed drugs across the Relapsing Multiple Sclerosis (RMS). A key objective of DelveInsight’s report is to establish the understanding for API Manufacturers for marketed and Phase III Pipeline drugs across the different ...  |  read more...
USD 2,000
4  5  6  7    9    11  12  13